Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

EuroIntervention 2015;10:1272-1275 published online ahead of print August 2014. DOI: 10.4244/EIJY14M08_07

Koen Teeuwen
Koen Teeuwen1, MD; Ben J.L. Van den Branden2, MD, PhD; Jacques J. Koolen3, MD, PhD; René J. van der Schaaf4, MD, PhD; José P.S. Henriques5, MD, PhD; Jan G.P. Tijssen6, MD, PhD; Johannes C. Kelder7, MD, PhD; Paul H.M.J. Vermeersch8, MD, PhD; Benno J.W.M. Rensing1, MD, PhD; Maarten J. Suttorp1*, MD, PhD
1. Department of Interventional Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; 2. Department of Interventional Cardiology, Amphia Hospital, Breda, The Netherlands; 3. Department of Interventional Cardiology, Catharina Hospital, Eindhoven,

Aims: Sirolimus-eluting stents (SES) have been shown to be superior to Endeavor zotarolimus-eluting stents (ZES) and comparable to Resolute ZES at eight-month angiography in patients trea

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

angioplastychronic total occlusionclinical research
Read next article
Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Latest news